Fri, Oct 24, 2014, 1:05 PM EDT - U.S. Markets close in 2 hrs 55 mins


% | $
Quotes you view appear here for quick access.


  • mr.k2626 mr.k2626 Sep 3, 2013 8:37 AM Flag

    What we know!

    Here are a few things we now know about the treatment ACTC is producing!

    Here is the part about the SMD patient going to 15 Letters!!

    0010| As further described below, the visual acuity of the Stargardt's patient improved from hand motions only to 20/800 vision. Before treatment, the patient was unable to read any letter on the ETDRS visual acuity chart. However, by two weeks posttransplantation, she was able to start reading letters, which improved to five letters at one to three months and 15 letters at one year in the treated eye (20/500 vision).

    This does seem to suggest the progress continues for a year!!! The above is from the recent patent applications posted earlier!

    No Patients have lost any visual acuity after treatment, amazing for a degenerative disease! So with early detection, the disease can be halted in its tracks!

    The ACTC study is being sited by numerous medical/research professionals all over the world!!! 119 times sited for one of the lancet paper from a single source!!!

    The costs of producing a single dose is approximately $100.00, what will be the charge for stopping blindness, current treatments for Wey AMD are approximately $25,000.00 annually!

    The financial messes from the past are being addressed and corrected!!!

    Anyone have anything to add?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
6.90+0.02(+0.29%)12:39 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.